Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 41 of 48 for:    "Depressive Disorder" [DISEASE] | ( Map: Vermont, United States )

Medibio DDA Confirmatory Performance Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03529513
Recruitment Status : Completed
First Posted : May 18, 2018
Last Update Posted : May 18, 2018
Sponsor:
Information provided by (Responsible Party):
Medibio Limited

Brief Summary:
This study will determine whether the Medibio Depression Diagnostic Aid exceeds minimally acceptable thresholds for sensitivity and sensitivity in cases with a current depression episode and non-depressed controls.

Condition or disease Intervention/treatment
Major Depressive Episode Diagnostic Test: Medibio Depression Diagnostic Aid Diagnostic Test: Mini International Neuropsychiatric Interview Diagnostic Test: Hamilton Rating Scale for Depression - 17 Item

Detailed Description:

Subjects meeting study criteria will be enrolled into one of two study cohorts: a) outpatient individuals with current, moderate-to-severe major depressive episode (experimental group) and b) individuals without current major depressive episode that have been matched at the group level for age and gender (control group).

All subjects will undergo two separate psychiatric interviews to confirm current depression episode presence or absence. Thereafter subjects will wear a heart rate monitor on the chest to capture data over the course of 72 hours. Subjects will return approximately 1 week after initial placement of the monitor for equipment return and a safety check. Subjects will wear a heart-rate monitor over the course of 72 hours. Subjects will return within a week from the last visit for equipment return.


Layout table for study information
Study Type : Observational
Actual Enrollment : 234 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Medibio Depression Diagnostic Aid Confirmatory Performance Study
Actual Study Start Date : August 18, 2017
Actual Primary Completion Date : May 4, 2018
Actual Study Completion Date : May 4, 2018

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Depressed
Subjects currently experiencing a moderate-to-severe major depressive episode are clinically evaluated over approximately 2-week period. 24-hour ECG data recordings are collected during each of the two weeks. Subjects may continue on current treatment regimen.
Diagnostic Test: Medibio Depression Diagnostic Aid
The Medibio DDA processes the heart rate and actigraphy data from the third-party devices, characterizes these data in comparison to the benchmark patterns of persons currently experiencing a depressive episode.

Diagnostic Test: Mini International Neuropsychiatric Interview
The Mini International Neuropsychiatric Interview (M.I.N.I.) is a structured diagnostic interview that was developed as a simple tool to assist clinicians to conduct psychiatric diagnoses according to the DSM-IV and International Statistical Classification of Diseases and Related Health Problems tenth revision (ICD-10) criteria.
Other Name: M.I.N.I.

Diagnostic Test: Hamilton Rating Scale for Depression - 17 Item
The clinician-administered Hamilton Depression Rating Scale (also known as the HAM-D) is the most widely used depression assessment scale . The original version contains 17 items (HDRS17) pertaining to symptoms of depression experienced over the past week. There are numerous versions with varying lengths that include the HDRS21, HDRS24, and HDRS29. This study will utilize the HDRS17 (HAMD-17) version.
Other Name: HAMD-17

Control
Subjects not currently experiencing a major depressive episode are clinically evaluated over approximately 2-week period. 24-hour ECG data recordings are collected during each of the two weeks. Subjects may continue on current treatment regimen.
Diagnostic Test: Medibio Depression Diagnostic Aid
The Medibio DDA processes the heart rate and actigraphy data from the third-party devices, characterizes these data in comparison to the benchmark patterns of persons currently experiencing a depressive episode.

Diagnostic Test: Mini International Neuropsychiatric Interview
The Mini International Neuropsychiatric Interview (M.I.N.I.) is a structured diagnostic interview that was developed as a simple tool to assist clinicians to conduct psychiatric diagnoses according to the DSM-IV and International Statistical Classification of Diseases and Related Health Problems tenth revision (ICD-10) criteria.
Other Name: M.I.N.I.

Diagnostic Test: Hamilton Rating Scale for Depression - 17 Item
The clinician-administered Hamilton Depression Rating Scale (also known as the HAM-D) is the most widely used depression assessment scale . The original version contains 17 items (HDRS17) pertaining to symptoms of depression experienced over the past week. There are numerous versions with varying lengths that include the HDRS21, HDRS24, and HDRS29. This study will utilize the HDRS17 (HAMD-17) version.
Other Name: HAMD-17




Primary Outcome Measures :
  1. Measure heart rate variability [ Time Frame: Up to 2 weeks ]
    The Medibio Algorithm will process data from subject 24-hour ECG data recordings.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Subjects who may be currently experiencing an episode of depression that are being diagnosed or treated in a mental health setting.
Criteria

All Subjects:

Inclusion Criteria:

  • Subject is willing and able to provide consent.
  • Subject has ability to read and understand the instructions for the study.
  • Subject is willing to adhere to study procedures.

Exclusion Criteria:

  • Subject has active psychotic symptoms.
  • Subject has bipolar disorder.
  • Subject has known, or is suspected to have a personality disorder.
  • Subject has current suicidality of medium or high risk as determined by M.I.N.I. or HAMD-17 item #3 score of 3 of higher.
  • Subject has history of central or obstructive sleep apnea OR STOP-BANG questionnaire score of ≥5.
  • Subject has a pacemaker.
  • Subject currently uses benzodiazepines on a scheduled basis.
  • Subject currently uses chronotropic medication, such as beta-blockers, digoxin, sinoatrial/atrioventricular nodal-acting calcium channel blockers, or amiodarone.
  • Subject is suspected or known to have active alcohol or drug abuse (including but not limited to abuse of marijuana).
  • Subject has a terminal illness.
  • For female subjects, subject is currently known to be pregnant or lactating.
  • Subject has any other acute or chronic condition that in the investigators opinion would preclude the subject from being able to meet all of the protocol requirements, or would compromise the subject's safety during participation in the study, as judged by the investigator.
  • Subject is currently participating in another clinical study. Subject currently uses antipsychotic medication for any indication.

Depressed Cohort Inclusion Criteria: Subject has current moderate or severe Major Depressive Disorder Episode, based on DSM-IV criteria for diagnosis as documented by clinician administered M.I.N.I plus HAMD-17 rating scale score ≥17.

Exclusion Criteria: Subject has presence of no or mild Major Depressive Disorder Episode, based on DSM-IV criteria for diagnosis as documented by clinician administered M.I.N.I OR HAMD-17 rating scale score <17.

Control Cohort Inclusion Criteria: Subject has no presence of mild, moderate, or severe Major Depressive Disorder Episode, based on DSM-IV criteria for diagnosis as documented by clinician administered M.I.N.I AND HAMD-17 rating scale score ≤7.

Exclusion Criteria: Subject has presence of mild, moderate, or severe Major Depressive Disorder Episode, based on DSM-IV criteria for diagnosis as documented by clinician administered M.I.N.I OR HAMD-17 rating scale score >7.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03529513


Locations
Layout table for location information
United States, California
CNS Network
Garden Grove, California, United States, 92845
CNS Network
Torrance, California, United States, 90502
United States, Ohio
Lindner Center of HOPE
Mason, Ohio, United States, 45040
United States, Oregon
OCCI, Inc.
Salem, Oregon, United States, 97301
United States, Texas
FutureSearch Trials
Dallas, Texas, United States, 75231
United States, Vermont
White River Junction Veterans Affairs Medical Center
White River Junction, Vermont, United States, 05009
Australia, Victoria
Epworth Clinic
Camberwell, Victoria, Australia, 3124
The Melbourne Clinic
Richmond, Victoria, Australia, 3121
Sponsors and Collaborators
Medibio Limited

Layout table for additonal information
Responsible Party: Medibio Limited
ClinicalTrials.gov Identifier: NCT03529513     History of Changes
Other Study ID Numbers: MB-DEPDX04
First Posted: May 18, 2018    Key Record Dates
Last Update Posted: May 18, 2018
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: IPD will not be shared with other researchers.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Pediatric Postmarket Surveillance of a Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder, Major
Depressive Disorder
Mood Disorders
Mental Disorders